ANN ARBOR, Mich., Nov. 8, 2018 /PRNewswire/ -- Strata Oncology, a leading precision oncology company, today announced the appointment of Scott A. Tomlins, M.D., Ph.D., as the Company's Chief Medical Officer. Dr. Tomlins is a leading molecular pathologist and cancer genomics researcher.
"We are thrilled to have Scott, one of Strata's co-founders, join our team full-time," said Dan Rhodes, Ph.D., Chief Executive Officer of Strata Oncology. "As we continue to scale and deliver on the promise of our precision oncology platform, Scott's unrivaled expertise in precision cancer diagnostics and translational research will be critical to achieving our objectives."
Dr. Tomlins brings to Strata Oncology extensive experience in cancer genomics, laboratory test development and delivery, and translational research. Prior to joining the company, Dr. Tomlins was an Associate Professor of Pathology at the University of Michigan, where his research focused on using high-throughput techniques to characterize the cancer genome and transcriptome to understand cancer biology and identify clinically relevant biomarkers and therapeutic targets. Among his many contributions to the field is the discovery and characterization of TMPRSS2:ETS gene fusions in prostate cancer. As a practicing pathologist, he led the translation of ETS gene fusions into diagnostic and early detection biomarkers. Dr. Tomlins' laboratory also developed, validated and applied multiple next generation sequencing approaches applicable to a variety of biospecimens.
Dr. Tomlins has received numerous academic honors and awards, holds multiple issued patents, and has co-authored over 200 manuscripts and textbook chapters. He received his M.D. and Ph.D. at the University of Michigan Medical School and completed a residency in Anatomic Pathology at the University of Michigan Health System. Dr. Tomlins is maintaining an adjunct faculty position at the University of Michigan Medical School.
About Strata Oncology
Strata Oncology is a precision medicine company dedicated to transforming cancer care by systematizing precision oncology across a network of health systems and pharma companies. We empower health systems to deliver a cost-effective, system-wide precision oncology program, one that integrates cutting-edge molecular profiling and precision therapy trials with routine care, so that all advanced cancer patients have the opportunity to benefit. This large network of trial-ready health systems provides a mechanism to rapidly and predictably enroll precision therapy trials. For more information visit www.strataoncology.com.
Strata Oncology Media Relations
SOURCE STRATA ONCOLOGY